Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A carcinoma that arises from the major salivary glands. It usually arises from the parotid gland. It is the most common primary carcinoma of the salivary glands and usually presents as a firm and painless mass. It is characterized by the presence of epidermoid cells, mucus producing cells, and cells of intermediate type. The majority of cases have a favorable outcome.
Biomarker and diagnostic research for major salivary gland mucoepidermoid carcinoma has been reported in the published literature.
No clinical trials have been registered for major salivary gland mucoepidermoid carcinoma.
42 publications have been identified in PubMed for major salivary gland mucoepidermoid carcinoma. Research spans Epidemiology / Natural History (33%), Case Report / Case Series (31%), and Clinical Trial Publication (12%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 14 | 33% |
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 5:41 PM UTC
Patient case studies |
13 |
31% |
Clinical study results | 5 | 12% |
Laboratory research | 4 | 10% |
Testing and diagnosis research | 3 | 7% |
Research summaries | 3 | 7% |
Zhang Y (2026). [PMID: 40829871](https://pubmed.ncbi.nlm.nih.gov/40829871/). *Journal of clinical pathology*. [Case Report / Case Series]
Aljarba M (2026). [PMID: 42041635](https://pubmed.ncbi.nlm.nih.gov/42041635/). *Diseases*. [Epidemiology / Natural History]
Al-Sajee D (2026). [PMID: 41128545](https://pubmed.ncbi.nlm.nih.gov/41128545/). *The American journal of surgical pathology*. [Epidemiology / Natural History]
Farhadi A (2026). [PMID: 41994062](https://pubmed.ncbi.nlm.nih.gov/41994062/). *J Dent (Shiraz)*. [Epidemiology / Natural History]
Kang K (2026). [PMID: 41593456](https://pubmed.ncbi.nlm.nih.gov/41593456/). *BMC oral health*. [Case Report / Case Series]
Kaur K (2026). [PMID: 41841047](https://pubmed.ncbi.nlm.nih.gov/41841047/). *Cureus*. [Case Report / Case Series]
Kundi FCS (2026). [PMID: 41505004](https://pubmed.ncbi.nlm.nih.gov/41505004/). *Head and neck pathology*. [Case Report / Case Series]
Jansen L (2026). [PMID: 41475047](https://pubmed.ncbi.nlm.nih.gov/41475047/). *European journal of cancer (Oxford, England : 1990)*. [Epidemiology / Natural History]
Mayer M (2026). [PMID: 41416670](https://pubmed.ncbi.nlm.nih.gov/41416670/). *Cancer cytopathology*. [Epidemiology / Natural History]
Panda S (2026). [PMID: 41680505](https://pubmed.ncbi.nlm.nih.gov/41680505/). *European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery*. [Epidemiology / Natural History]
AI-curated news mentioning major salivary gland mucoepidermoid carcinoma
Updated Sep 11, 2026
A cohort study involving 892 patients across 21 centers provides external validation for the UICC 9th edition N-classification in major salivary gland carcinomas. This research enhances understanding of disease classification and may influence future treatment strategies.
A multicenter study identifies key prognostic factors influencing survival after recurrence in major salivary gland carcinomas. This research provides valuable insights that could inform treatment strategies and patient management.
Research indicates that a high density of T-cell lymphocytes and regulatory T cells (Tregs) is associated with poorer survival outcomes in patients with major salivary gland carcinomas. This finding could influence future therapeutic strategies targeting immune cell populations.